TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.5. MAJOR MARKET FINDINGS
2.5.1. AIR POLLUTION IS A MAJOR CAUSE OF EYE DISEASES
2.5.2. COVID-19 CONTRIBUTED TO A HIGH NUMBER OF DRY EYE DISEASE CASES
2.5.3. ASIAN RACE IS AT HIGHER RISK OF DEVELOPING DRY EYE DISEASE
2.5.4. EXCESSIVE SCREEN TIME CAN INDUCE DRY EYE SYMPTOMS
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. INTRODUCTION OF NOVEL DIAGNOSTIC TECHNIQUES FOR DRY EYE DISEASE
3.1.2. LAUNCH OF PROMISING PIPELINE PRODUCTS FOR DRY EYE DISEASE
3.1.3. GROWING INCIDENCE AND PREVALENCE OF DRY EYE AMONG DIFFERENT AGE GROUPS
3.2. KEY RESTRAINTS
3.2.1. RISK OF SIDE EFFECTS
3.2.2. SUBSTITUTE THERAPIES
3.2.3. EXPENSIVE SPECIALTY PRODUCTS AND COMPLEX REIMBURSEMENT SCENARIO
4. KEY ANALYTICS
4.1. PARENT MARKET ANALYSIS
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
4.7. VALUE CHAIN ANALYSIS
4.7.1. RESEARCH AND DEVELOPMENT
4.7.2. MANUFACTURING
4.7.3. DISTRIBUTORS
4.7.4. POST-SALES MONITORING
5. MARKET BY TYPE
5.1. OTC
5.2. PRESCRIPTION
6. MARKET BY PRODUCT
6.1. ANTI-INFLAMMATORY DRUGS
6.1.1. CYCLOSPORINE
6.1.2. CORTICOSTEROID
6.1.3. OTHER ANTI-INFLAMMATORY DRUGS
6.2. ARTIFICIAL TEARS
6.3. PUNCTAL PLUGS
6.4. SECRETAGOGUES
6.5. OTHER PRODUCTS
7. MARKET BY DISTRIBUTION CHANNEL
7.1. HOSPITAL PHARMACIES
7.2. INDEPENDENT PHARMACIES AND DRUGSTORES
7.3. ONLINE PHARMACIES
8. GEOGRAPHICAL ANALYSIS
8.1. NORTH AMERICA
8.1.1. MARKET SIZE & ESTIMATES
8.1.2. NORTH AMERICA DRY EYE DISEASE MARKET DRIVERS
8.1.3. NORTH AMERICA DRY EYE DISEASE MARKET CHALLENGES
8.1.4. NORTH AMERICA DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
8.1.5. KEY PLAYERS IN NORTH AMERICA DRY EYE DISEASE MARKET
8.1.6. COUNTRY ANALYSIS
8.1.6.1. UNITED STATES
8.1.6.1.1. UNITED STATES DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.1.6.2. CANADA
8.1.6.2.1. CANADA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.2. EUROPE
8.2.1. MARKET SIZE & ESTIMATES
8.2.2. EUROPE DRY EYE DISEASE MARKET DRIVERS
8.2.3. EUROPE DRY EYE DISEASE MARKET CHALLENGES
8.2.4. EUROPE DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
8.2.5. KEY PLAYERS IN EUROPE DRY EYE DISEASE MARKET
8.2.6. COUNTRY ANALYSIS
8.2.6.1. UNITED KINGDOM
8.2.6.1.1. UNITED KINGDOM DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.2.6.2. GERMANY
8.2.6.2.1. GERMANY DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.2.6.3. FRANCE
8.2.6.3.1. FRANCE DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.2.6.4. ITALY
8.2.6.4.1. ITALY DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.2.6.5. BELGIUM
8.2.6.5.1. BELGIUM DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.2.6.6. SPAIN
8.2.6.6.1. SPAIN DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.2.6.7. POLAND
8.2.6.7.1. POLAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.2.6.8. REST OF EUROPE
8.2.6.8.1. REST OF EUROPE DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.3. ASIA-PACIFIC
8.3.1. MARKET SIZE & ESTIMATES
8.3.2. ASIA-PACIFIC DRY EYE DISEASE MARKET DRIVERS
8.3.3. ASIA-PACIFIC DRY EYE DISEASE MARKET CHALLENGES
8.3.4. ASIA-PACIFIC DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
8.3.5. KEY PLAYERS IN ASIA-PACIFIC DRY EYE DISEASE MARKET
8.3.6. COUNTRY ANALYSIS
8.3.6.1. CHINA
8.3.6.1.1. CHINA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.3.6.2. JAPAN
8.3.6.2.1. JAPAN DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.3.6.3. INDIA
8.3.6.3.1. INDIA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.3.6.4. SOUTH KOREA
8.3.6.4.1. SOUTH KOREA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.3.6.5. INDONESIA
8.3.6.5.1. INDONESIA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.3.6.6. THAILAND
8.3.6.6.1. THAILAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.3.6.7. AUSTRALIA & NEW ZEALAND
8.3.6.7.1. AUSTRALIA & NEW ZEALAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.3.6.8. REST OF ASIA-PACIFIC
8.3.6.8.1. REST OF ASIA-PACIFIC DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.4. REST OF WORLD
8.4.1. MARKET SIZE & ESTIMATES
8.4.2. REST OF WORLD DRY EYE DISEASE MARKET DRIVERS
8.4.3. REST OF WORLD DRY EYE DISEASE MARKET CHALLENGES
8.4.4. REST OF WORLD DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
8.4.5. KEY PLAYERS IN REST OF WORLD DRY EYE DISEASE MARKET
8.4.6. REGIONAL ANALYSIS
8.4.6.1. LATIN AMERICA
8.4.6.1.1. LATIN AMERICA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.4.6.2. MIDDLE EAST AND AFRICA
8.4.6.2.1. MIDDLE EAST AND AFRICA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9. COMPETITIVE LANDSCAPE
9.1. KEY STRATEGIC DEVELOPMENTS
9.1.1. MERGERS & ACQUISITIONS
9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
9.1.3. PARTNERSHIPS & AGREEMENTS
9.1.4. BUSINESS EXPANSIONS & DIVESTITURES
9.2. COMPANY PROFILES
9.2.1. AFT PHARMACEUTICALS
9.2.2. ALCON
9.2.3. ALLERGAN PLC (ACQUIRED BY ABBVIE)
9.2.4. BAUSCH HEALTH COMPANIES INC
9.2.5. JOHNSON & JOHNSON
9.2.6. LUMENIS
9.2.7. NOVALIQ GMBH
9.2.8. NOVARTIS AG
9.2.9. OASIS MEDICAL
9.2.10. OTSUKA PHARMACEUTICAL CO LTD
9.2.11. SANTEN PHARMACEUTICAL CO LTD
9.2.12. SENTISS PHARMA PRIVATE LIMITED
9.2.13. SUN PHARMACEUTICAL INDUSTRIES LTD
9.2.14. TEVA PHARMACEUTICAL INDUSTRIES LTD
9.2.15. VISUFARMA
TABLE 1: MARKET SNAPSHOT – DRY EYE DISEASE
TABLE 2: GLOBAL DRY EYE DISEASE MARKET, BY TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 3: GLOBAL DRY EYE DISEASE MARKET, BY TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 4: GLOBAL OTC MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 5: GLOBAL OTC MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 6: GLOBAL PRESCRIPTION MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 7: GLOBAL PRESCRIPTION MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 8: GLOBAL DRY EYE DISEASE MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 9: GLOBAL DRY EYE DISEASE MARKET, BY PRODUCT, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 10: GLOBAL DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 11: GLOBAL DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 12: GLOBAL CYCLOSPORINE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 13: GLOBAL CYCLOSPORINE MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 14: GLOBAL CORTICOSTEROID MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 15: GLOBAL CORTICOSTEROID MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 16: GLOBAL OTHER ANTI-INFLAMMATORY DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 17: GLOBAL OTHER ANTI-INFLAMMATORY DRUGS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 18: GLOBAL ARTIFICIAL TEARS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 19: GLOBAL ARTIFICIAL TEARS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 20: GLOBAL PUNCTAL PLUGS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 21: GLOBAL PUNCTAL PLUGS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 22: GLOBAL SECRETAGOGUES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 23: GLOBAL SECRETAGOGUES MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 24: GLOBAL OTHER PRODUCTS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 25: GLOBAL OTHER PRODUCTS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 26: GLOBAL DRY EYE DISEASE MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 27: GLOBAL DRY EYE DISEASE MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 28: GLOBAL HOSPITAL PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 29: GLOBAL HOSPITAL PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 30: GLOBAL INDEPENDENT PHARMACIES AND DRUGSTORES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 31: GLOBAL INDEPENDENT PHARMACIES AND DRUGSTORES MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 32: GLOBAL ONLINE PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 33: GLOBAL ONLINE PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 34: GLOBAL DRY EYE DISEASE MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 35: GLOBAL DRY EYE DISEASE MARKET, BY GEOGRAPHY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 36: NORTH AMERICA DRY EYE DISEASE MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 37: NORTH AMERICA DRY EYE DISEASE MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 38: NORTH AMERICA DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
TABLE 39: KEY PLAYERS OPERATING IN NORTH AMERICA DRY EYE DISEASE MARKET
TABLE 40: EUROPE DRY EYE DISEASE MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 41: EUROPE DRY EYE DISEASE MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 42: EUROPE DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
TABLE 43: KEY PLAYERS OPERATING IN EUROPE DRY EYE DISEASE MARKET
TABLE 44: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 45: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 46: ASIA-PACIFIC DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
TABLE 47: KEY PLAYERS OPERATING IN ASIA-PACIFIC DRY EYE DISEASE MARKET
TABLE 48: REST OF WORLD DRY EYE DISEASE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 49: REST OF WORLD DRY EYE DISEASE MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 50: REST OF WORLD DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
TABLE 51: KEY PLAYERS OPERATING IN REST OF WORLD DRY EYE DISEASE MARKET
TABLE 52: LIST OF MERGERS & ACQUISITIONS
TABLE 53: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 54: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 55: LIST OF BUSINESS EXPANSIONS & DIVESTITURES
| ※参考情報 ドライアイ疾患(ドライアイ)は、目の表面が乾燥し、様々な不快な症状を引き起こす状態を指します。涙液の量や質の異常が原因で、目の保護や潤滑が十分に行われないことから発症します。ドライアイは、視覚の乱れや目の痛み、かゆみなどが主な症状として現れ、生活の質を大きく損なう可能性があります。 ドライアイにはいくつかの種類があり、主に涙液の分泌不足によって起こる「水分型」と、涙液の蒸発が過剰に起きる「蒸発型」に分けられます。水分型のドライアイは、主に涙腺の機能低下によるものが多く、加齢や疾患、特定の薬剤が影響しています。一方、蒸発型のドライアイは、環境要因やまばたきの頻度の低下、腺の障害が関与しています。また、これらの型は併発することもあり、患者によって症状の現れ方は異なります。 ドライアイの用途としては、主に症状の緩和や視力の改善が挙げられます。治療法としては、人工涙液や点眼薬の使用が一般的で、これにより一時的に目の乾燥を緩和し、快適さを提供します。また、患者の状態に応じて、涙の分泌を促す内服薬や、涙液の蒸発を防ぐための目の周りのケアが含まれることもあります。重症の場合は、涙点塞栓術という手術が行われることもあります。 関連技術としては、ドライアイの診断や治療に役立つさまざまな機器や方法があります。まず、ドライアイを診断するための検査がいくつか存在します。例えば、涙液量を測定するためのシュマーフィルムテストや、涙液の質を評価するためのオスモラリティテストなどがあります。これらの検査を通じて、適切な治療法を選択し、患者に合わせたケアが行われます。 さらに、ドライアイの治療においては、最新の技術も注目されています。一つは、脂質を含む人工涙液の開発です。涙の蒸発を防ぎ、従来の水分型の人工涙液よりも持続性が高いとされています。また、眼科用の生理食塩水を含む目のマスクや、特殊なサングラスなども登場しており、これらは日常生活の中で目を保護し、快適さを向上させる役割を果たしています。 最近の研究では、幹細胞を活用した治療や、炎症を抑える新しい薬剤の開発も進められています。ドライアイは慢性的な状態になりやすいため、性的なアプローチが求められることがあります。これら新しいアプローチが確立されることで、より効果的な治療法が提供されることが期待されます。 ドライアイ疾患は、生活習慣や環境にも影響を受けるため、日常的な予防策も重要です。エアコンや暖房の使用を控える、目をこまめに休ませる、十分な水分を摂取するなど、対策を講じることで、症状の軽減が図れる場合があります。また、長時間のデジタルデバイスの使用を避けたり、適度な頻度でまばたきを意識したりすることも効果的です。 患者と医療従事者の連携が重要で、適切な診断と治療を受けることで、ドライアイの影響を最小限に抑えることができます。治療法の選択肢は日々進化しており、最新の情報を元に対応策を見つけることが求められます。それにより、ドライアイによって引き起こされる生活の質の低下を防ぐことができるでしょう。この疾患に対する理解を深め、適切なケアを行うことが、健康的な生活を維持するために欠かせない要素となります。 |
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/

